SPLUNC1 in Severe Asthma

SPLUNC1 治疗严重哮喘

基本信息

  • 批准号:
    9174103
  • 负责人:
  • 金额:
    $ 4.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-15 至 2019-04-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Severe asthma afflicts about 10% of asthma patients, but utilizes 30 to 50% asthma-associated healthcare costs. It is imperative to understand the mechanisms by which severe asthma in particular acute exacerbation develops. To improve the understanding of severe asthma and to develop better treatments, for the last 14 years, NIH/NHLBI has funded the Severe Asthma Research Program (SARP), the world's most comprehensive study of adults and children with severe asthma that are currently performed at seven leading asthma research sites in the US. The current SARP (SARP3) has started collecting upper and lower airway samples to study severe asthma pathobiology. This offers an unprecedented opportunity to further our understanding of natural history of asthma, disease progression and new therapeutic interventions. However, SARP3 protocols do not include the collection of minimally invasive nasal airway epithelial cells, an approach that can be repeated longitudinally to study asthma pathogenesis. Thus, we propose a time-sensitive study by using nasal airway epithelial cells to determine the role of a novel host defense protein SPLUNC1 in severe asthma. Short palate, lung, and nasal epithelium clone 1 (SPLUNC1) is a secretory protein from large airway (nasal, tracheal and bronchial) epithelial cells and is abundant in the epithelial lining fluid of healthy individuals. Through collaboration with SARP investigators, we identified SPLUNC1 as one of the most significantly decreased proteins in bronchoalveolar lavage fluid samples from severe asthmatics. We have found that SPLUNC1 exerts host defense functions against human rhinoviruses and bacteria involved in asthma exacerbations - a leading cause of morbidity, mortality and health care costs in asthma. We discovered SPLUNC1-deficient mice have exaggerated airway allergic inflammation following allergen challenges (e.g., eosinophils and mucus, relevant to asthma exacerbations). Moreover, transgenic over-expression of human SPLUNC1 in mouse airways attenuates allergen-induced eosinophilic inflammation. However, the role of SPLUNC1 in human severe asthma is unclear. We hypothesize that down-regulation of SPLUNC1 in asthmatic airways increases rhinovirus infection and associated asthma exacerbations contributing to asthma severity. In continuing collaboration with SARP and its data coordination center, we will define the role of SPLUNC1 in severe asthma phenotypes. Furthermore, we will team up with 4 SARP sites to collect brushed live nasal airway epithelial cells from asthmatic children and adults during asthma exacerbations to determine if lower baseline SPLUNC1 levels predispose the patients to rhinovirus infection and asthma exacerbations. Finally, we will mechanistically determine SPLUNC1's anti-viral and anti-inflammatory functions that are critical to the prevention of asthma exacerbations. Successful completion of this time-sensitive ancillary R01 proposal will guide use of SPLUNC1 as a biomarker and a new therapy to prevent or treat acute asthma exacerbations.
 描述(由申请人提供):约 10% 的哮喘患者患有严重哮喘,但占用了 30% 至 50% 的哮喘相关医疗费用。必须了解严重哮喘尤其是急性发作的发生机制。为了提高对严重哮喘的了解并开发更好的治疗方法,在过去 14 年中,NIH/NHLBI 资助了严重哮喘研究计划 (SARP),这是世界上最全面的针对患有严重哮喘的成人和儿童的研究,目前正在美国七个领先的哮喘研究中心进行。目前的标准和建议措施 (SARP3) 已开始收集上呼吸道和下呼吸道样本以研究严重哮喘病理学。这为进一步了解哮喘自然史、疾病进展和新的治疗干预措施提供了前所未有的机会。然而,SARP3 方案不包括微创鼻气道上皮细胞的收集,这是一种可以纵向重复以研究哮喘发病机制的方法。因此,我们提出了一项时间敏感的研究,通过使用鼻气道上皮细胞来确定新型宿主防御蛋白 SPLUNC1 在严重哮喘中的作用。短腭、肺和鼻上皮克隆 1 (SPLUNC1) 是一种来自大气道(鼻、气管和支气管)上皮细胞的分泌蛋白,在健康个体的上皮衬里液中含量丰富。通过与 SARP 研究人员合作,我们发现 SPLUNC1 是严重哮喘患者支气管肺泡灌洗液样本中减少最显着的蛋白质之一。我们发现,SPLUNC1 发挥宿主防御功能,抵抗与哮喘恶化有关的人类鼻病毒和细菌,而哮喘恶化是哮喘发病、死亡和医疗费用的主要原因。我们发现 SPLUNC1 缺陷的小鼠在过敏原挑战(例如,与哮喘恶化相关的嗜酸性粒细胞和粘液)后气道过敏性炎症加剧。此外,人 SPLUNC1 在小鼠气道中的转基因过度表达可减轻过敏原诱导的嗜酸性粒细胞炎症。然而,SPLUNC1 在人类严重哮喘中的作用尚不清楚。我们假设哮喘气道中 SPLUNC1 的下调会增加鼻病毒感染和相关的哮喘恶化,从而导致哮喘严重程度。在与 SARP 及其数据协调中心的持续合作中,我们将定义 SPLUNC1 在严重哮喘表型中的作用。此外,我们将与 4 个 SARP 中心合作,在哮喘恶化期间收集哮喘儿童和成人的活鼻气道上皮细胞,以确定较低的基线 SPLUNC1 水平是否会使患者容易受到鼻病毒感染和哮喘恶化。最后,我们将从机制上确定 SPLUNC1 的抗病毒和抗炎功能,这对于预防哮喘恶化至关重要。 这项时间敏感的辅助 R01 提案的成功完成将指导使用 SPLUNC1 作为生物标志物和预防或治疗哮喘急性发作的新疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hong W Chu其他文献

Hong W Chu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hong W Chu', 18)}}的其他基金

Role of immunoproteasome in airway viral infection
免疫蛋白酶体在气道病毒感染中的作用
  • 批准号:
    10155416
  • 财政年份:
    2020
  • 资助金额:
    $ 4.44万
  • 项目类别:
Parkin in mitochondrial dysfunction and airway inflammation of obese asthma
Parkin 在肥胖哮喘线粒体功能障碍和气道炎症中的作用
  • 批准号:
    10264924
  • 财政年份:
    2020
  • 资助金额:
    $ 4.44万
  • 项目类别:
Role of immunoproteasome in airway viral infection
免疫蛋白酶体在气道病毒感染中的作用
  • 批准号:
    10398121
  • 财政年份:
    2020
  • 资助金额:
    $ 4.44万
  • 项目类别:
Parkin in mitochondrial dysfunction and airway inflammation of obese asthma
Parkin 在肥胖哮喘线粒体功能障碍和气道炎症中的作用
  • 批准号:
    10457989
  • 财政年份:
    2020
  • 资助金额:
    $ 4.44万
  • 项目类别:
Role of immunoproteasome in airway viral infection
免疫蛋白酶体在气道病毒感染中的作用
  • 批准号:
    10610373
  • 财政年份:
    2020
  • 资助金额:
    $ 4.44万
  • 项目类别:
Parkin in mitochondrial dysfunction and airway inflammation of obese asthma
Parkin 在肥胖哮喘线粒体功能障碍和气道炎症中的作用
  • 批准号:
    10675493
  • 财政年份:
    2020
  • 资助金额:
    $ 4.44万
  • 项目类别:
Immunosuppressive injurious effects of e-cigarettes on human lung parenchyma
电子烟对人体肺实质的免疫抑制损伤作用
  • 批准号:
    10005959
  • 财政年份:
    2018
  • 资助金额:
    $ 4.44万
  • 项目类别:
Immunosuppressive injurious effects of e-cigarettes on human lung parenchyma
电子烟对人体肺实质的免疫抑制损伤作用
  • 批准号:
    10241973
  • 财政年份:
    2018
  • 资助金额:
    $ 4.44万
  • 项目类别:
Immunosuppressive injurious effects of e-cigarettes on human lung parenchyma
电子烟对人体肺实质的免疫抑制损伤作用
  • 批准号:
    9626290
  • 财政年份:
    2018
  • 资助金额:
    $ 4.44万
  • 项目类别:
Immunosuppressive injurious effects of e-cigarettes on human lung parenchyma
电子烟对人体肺实质的免疫抑制损伤作用
  • 批准号:
    9789355
  • 财政年份:
    2018
  • 资助金额:
    $ 4.44万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.44万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 4.44万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.44万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.44万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 4.44万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.44万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.44万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.44万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 4.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 4.44万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了